NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. GOOG
7. INTC
8. CSX
9. IBM
10. KNX

Go back to NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
(NASDAQ: ELDN) Delayed: 3.74 +0.02 (0.54%)
Previous Close $3.72    52 Week High $ 
Open $3.84    52 Week Low $ 
Day High $3.84    P/E N/A 
Day Low $3.62    EPS $ 
Volume 614,383